Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies
Identifieur interne : 000923 ( Main/Exploration ); précédent : 000922; suivant : 000924Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies
Auteurs : Stefanie Hennig [Suède] ; Joakim Nyberg [Suède] ; Andrew C. Hooker [Suède] ; Mats O. Karlsson [Suède]Source :
- The Journal of Clinical Pharmacology [ 0091-2700 ] ; 2009-03.
English descriptors
Abstract
Optimal design has been used in the past mainly to optimize sampling schedules for clinical trials. Optimization on design variables other than sampling times has been published in the literature only once before. This study shows, as an example, optimization on the length of treatment periods to obtain reliable estimates of drug effects on long‐term disease progression studies. Disease progression studies are high in cost, effort, and time; therefore, optimization of treatment length is highly recommended to avoid failure or loss of information. Results are provided for different drug effects (eg, protective and symptomatic) and for different lengths of studies and sampling schedules. The merits of extending the total study length versus inclusion of more samples per participants are investigated. The authors demonstrate that if no observations are taken during the washout period, a trial can lose up to 40% of its efficiency. Furthermore, when optimization of treatment length is performed using multiple possible drug effect models simultaneously, these studies show high power in discriminating between different drug effect models.
Url:
DOI: 10.1177/0091270008329560
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies</title><author><name sortKey="Hennig, Stefanie" sort="Hennig, Stefanie" uniqKey="Hennig S" first="Stefanie" last="Hennig">Stefanie Hennig</name></author><author><name sortKey="Nyberg, Joakim" sort="Nyberg, Joakim" uniqKey="Nyberg J" first="Joakim" last="Nyberg">Joakim Nyberg</name></author><author><name sortKey="Hooker, Andrew C" sort="Hooker, Andrew C" uniqKey="Hooker A" first="Andrew C." last="Hooker">Andrew C. Hooker</name></author><author><name sortKey="Karlsson, Mats O" sort="Karlsson, Mats O" uniqKey="Karlsson M" first="Mats O." last="Karlsson">Mats O. Karlsson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:922240324A323C0FBCA2B2CE150164095B004353</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1177/0091270008329560</idno><idno type="url">https://api.istex.fr/document/922240324A323C0FBCA2B2CE150164095B004353/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001051</idno><idno type="wicri:Area/Main/Curation">000E61</idno><idno type="wicri:Area/Main/Exploration">000923</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies</title><author><name sortKey="Hennig, Stefanie" sort="Hennig, Stefanie" uniqKey="Hennig S" first="Stefanie" last="Hennig">Stefanie Hennig</name><affiliation wicri:level="4"><country xml:lang="fr">Suède</country><wicri:regionArea>Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala</wicri:regionArea><orgName type="university">Université d'Uppsala</orgName><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName></affiliation></author><author><name sortKey="Nyberg, Joakim" sort="Nyberg, Joakim" uniqKey="Nyberg J" first="Joakim" last="Nyberg">Joakim Nyberg</name><affiliation wicri:level="4"><country xml:lang="fr">Suède</country><wicri:regionArea>Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala</wicri:regionArea><orgName type="university">Université d'Uppsala</orgName><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName></affiliation></author><author><name sortKey="Hooker, Andrew C" sort="Hooker, Andrew C" uniqKey="Hooker A" first="Andrew C." last="Hooker">Andrew C. Hooker</name><affiliation wicri:level="4"><country xml:lang="fr">Suède</country><wicri:regionArea>Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala</wicri:regionArea><orgName type="university">Université d'Uppsala</orgName><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName></affiliation></author><author><name sortKey="Karlsson, Mats O" sort="Karlsson, Mats O" uniqKey="Karlsson M" first="Mats O." last="Karlsson">Mats O. Karlsson</name><affiliation wicri:level="4"><country xml:lang="fr">Suède</country><wicri:regionArea>Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala</wicri:regionArea><orgName type="university">Université d'Uppsala</orgName><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Clinical Pharmacology</title><idno type="ISSN">0091-2700</idno><idno type="eISSN">1552-4604</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-03">2009-03</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="323">323</biblScope><biblScope unit="page" to="335">335</biblScope></imprint><idno type="ISSN">0091-2700</idno></series><idno type="istex">922240324A323C0FBCA2B2CE150164095B004353</idno><idno type="DOI">10.1177/0091270008329560</idno><idno type="ArticleID">JCPH5291</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0091-2700</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>clinical trial design</term><term>disease progression studies</term><term>optimal design</term><term>pharmacometrics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Optimal design has been used in the past mainly to optimize sampling schedules for clinical trials. Optimization on design variables other than sampling times has been published in the literature only once before. This study shows, as an example, optimization on the length of treatment periods to obtain reliable estimates of drug effects on long‐term disease progression studies. Disease progression studies are high in cost, effort, and time; therefore, optimization of treatment length is highly recommended to avoid failure or loss of information. Results are provided for different drug effects (eg, protective and symptomatic) and for different lengths of studies and sampling schedules. The merits of extending the total study length versus inclusion of more samples per participants are investigated. The authors demonstrate that if no observations are taken during the washout period, a trial can lose up to 40% of its efficiency. Furthermore, when optimization of treatment length is performed using multiple possible drug effect models simultaneously, these studies show high power in discriminating between different drug effect models.</div></front></TEI><affiliations><list><country><li>Suède</li></country><region><li>East Middle Sweden</li><li>Svealand</li></region><settlement><li>Uppsala</li></settlement><orgName><li>Université d'Uppsala</li></orgName></list><tree><country name="Suède"><region name="Svealand"><name sortKey="Hennig, Stefanie" sort="Hennig, Stefanie" uniqKey="Hennig S" first="Stefanie" last="Hennig">Stefanie Hennig</name></region><name sortKey="Hooker, Andrew C" sort="Hooker, Andrew C" uniqKey="Hooker A" first="Andrew C." last="Hooker">Andrew C. Hooker</name><name sortKey="Karlsson, Mats O" sort="Karlsson, Mats O" uniqKey="Karlsson M" first="Mats O." last="Karlsson">Mats O. Karlsson</name><name sortKey="Nyberg, Joakim" sort="Nyberg, Joakim" uniqKey="Nyberg J" first="Joakim" last="Nyberg">Joakim Nyberg</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000923 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000923 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:922240324A323C0FBCA2B2CE150164095B004353
|texte= Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies
}}
| This area was generated with Dilib version V0.6.23. |  |